An Intervention Study of Compound Silymarin in Patients With Non-alcoholic Fatty Liver Disease

Prior treatment

• Body weight change are more than 10% in previous 3 months;

Other illness

• Patients with certain hepatic diseases such as gallstones, hepatitis C, autoimmune hepatitis, and hepatolenticular degeneration which can lead to fatty liver disease;
• Patients with total parenteral nutrition, inflammatory bowel disease, celiac disease, hypothyroidism, Cushing syndrome, Mauriac syndrome, etc;
• Patients with hereditary diseases, coronary heart disease, mental disorder, cancer, cirrhosis and renal disease;
• Subjects are allergic to the ingredients in the test or control samples;

Other

• ≥ 30 grams of alcohol/day for male and ≥ 20 grams of alcohol/day for female;
• Be taking medicines or supplements that would influence the liver function, lipid metabolism;
• Patients who have participated in or are participating in other clinical trials within 3 months of their first administration of the study product;
• Woman who is pregnant or breastfeeding;
• Subjects cannot meet the requirements of compliance in the pre-experiment period;
• Subjects who fail to sign the informed consent forms.

• Subject's BMI is ≥ 22.0 kg/m2 and \< 33.0 kg/m2;
• Subject is diagnosed with NAFLD according to the Chinese Non-alcoholic fatty liver disease prevention guide 2018;
• A mildly elevated of ALT level (≥ 30 U/L for male, ≥ 19 U/L for female) or an AST/ALT ratio \< 1.0;
• Must be able to swallow tablets.